by April Breyer Menon | Mar 17, 2023
Reviewing the BPCIA litigations to date, we found that the number of patents asserted could play a role in the resolution of the litigation. 21 of the 46 (45.7%) BPCIA litigations involved five or fewer patents, 20 (43.5%) involved more than 10 patents, and 16...
by April Breyer Menon | Mar 17, 2023
*Biosimilar-related IPR outcomes by petition and by patent. IPRs that are still pending are not included. Settled / Terminated includes IPRs that were settled or terminated at the Petitioner’s request prior to a final written decision, and include IPRs terminated...
by April Breyer Menon | Mar 17, 2023
*Outcomes of terminated biosimilar-related IPRs by patent. Patents with no claims invalidated include those that were not instituted, as well as those with IPRs that were terminated without a final written decision. Patents with at least some claims invalidated...
by April Breyer Menon | Jun 6, 2025
2025 estimates are calculated based on statistics from January 1, 2025 through May 31, 2025. BiologicsHQ and materials published on BiologicsHQ are published for informational purposes only. Neither the information nor any opinion expressed on BiologicsHQ...
by April Breyer Menon | Jun 6, 2025
BiologicsHQ and materials published on BiologicsHQ are published for informational purposes only. Neither the information nor any opinion expressed on BiologicsHQ constitute legal advice, create an attorney-client relationship, or constitute a solicitation for...